---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-251319"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:28:06.419656+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Hideki Garren resigns from Coya board effective Nov 1, 2024

## Summary
- Dr. Hideki Garren resigned immediately to comply with new employer's policy barring board service on companies with similar therapeutic areas.
- Resignation was not due to any disagreement with Coya or its management on operations, policies, or practices.
- Board seat vacancy created; no replacement announced as of filing date.

## SEC filing metadata
- accession: 0001193125-24-251319
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312524251319/0001193125-24-251319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312524251319/d872629d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-251319
- JSON: https://secwatch.observer/filing/0001193125-24-251319.json
- Plain text: https://secwatch.observer/filing/0001193125-24-251319.txt

## Key facts
- Executive change
  Hideki Garren resigned as Director at Coya Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On November 1, 2024, Dr. Hideki Garren provided Coya Therapeutics, Inc. (the “Company”) with notice of his resignation from the Board of Directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312524251319/0001193125-24-251319-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.